Claims
- 1. A method for relieving respiratory congestion in a subject, comprising the step of administering in a manner so as not to effect gene transfer, a therapeutically effective amount of polynucleic acid in a pharmaceutically acceptable vehicle to a subject having a disease characterized by respiratory congestion, wherein said respiratory congestion is a result of an overproduction of viscous mucus or sputum lodged in said subject's respiratory tract, and wherein said method results in the reduced viscosity of said mucus or said sputum such that there is an increase of production and a reduced accumulation of mucus in said subject's respiratory tract; and
wherein said polynucleic acid is synthetic polynucleic acid.
- 2. The method according to claim 1, wherein said polynucleic acid is synthetic poly(dA):poly(dT) or poly(dG):poly(dC) DNA.
- 3. The method according to claim 1, wherein said disease is selected from the group consisting of cystic fibrosis, emphysema, bronchitis, and sinusitis.
- 4. The method according to claim 1, wherein said polynucleic acid is administered by a route selected from the group consisting of sublingual, subcutaneous, intravenous, intramuscular, and intrathecal administration.
- 5. The method according to claim 1, wherein said vehicle is selected from the group consisting of water, saline, albumin, or dextrose.
- 6. The method according to claim 1, wherein said effective amount of polynucleic acid is from about 1.2×10−7 mg to about 0.03 mg of synthetic polynucleic acid.
- 7. The method according to claim 1, wherein said effective amount of polynucleic acid is about 0.0003 mg of synthetic polynucleic acid.
- 8. The method according to claim 1, wherein said subject is a human.
- 9. A method for treating COPD symptoms in a subject, comprising the step of administering in a manner so as not to effect gene transfer, an effective amount of polynucleic acid in a pharmaceutically acceptable vehicle to a subject having COPD symptoms, wherein said polynucleic acid is synthetic polynucleic acid.
- 10. The method according to claim 9, wherein said polynucleic acid is synthetic poly(dA):poly(dT) or poly(dG):poly(dC) DNA.
- 11. The method according to claim 9, wherein said polynucleic acid is administered by a route selected from the group consisting of sublingual, subcutaneous, intravenous, intramuscular, and intrathecal administration.
- 12. The method according to claim 9, wherein said vehicle is selected from the group consisting of water, saline, albumin, or dextrose.
- 13. The method according to claim 9, wherein said effective amount of polynucleic acid is from about 1.2×10−7 mg to about 0.03 mg of synthetic polynucleic acid.
- 14. The method according to claim 9, wherein said effective amount of polynucleic acid is about 0.0003 mg of synthetic polynucleic acid.
- 15. The method according to claim 9, wherein said subject is a human.
- 16. A method for treating heaves symptoms in a subject, comprising the step of administering in a manner so as not to effect gene transfer, a therapeutically effective amount of polynucleic acid in a pharmaceutically acceptable vehicle to a subject having heaves symptoms, wherein said polynucleic acid is synthetic polynucleic acid.
- 17. The method according to claim 16, wherein said polynucleic acid is synthetic poly(dA):poly(dT) or poly(dG):poly(dC) DNA.
- 18. The method according to claim 16, wherein said polynucleic acid is administered by a route selected from the group consisting of sublingual, subcutaneous, intravenous, intramuscular, and intrathecal administration.
- 19. The method according to claim 16, wherein said vehicle is selected from the group consisting of water, saline, albumin, or dextrose.
- 20. The method according to claim 16, wherein said effective amount of polynucleic acid is from about 1.2×107 mg to about 0.03 mg of synthetic polynucleic acid.
- 21. The method according to claim 16, wherein said effective amount of polynucleic acid is about 0.0003 mg of synthetic polynucleic acid.
- 22. The method according to claim 16, wherein said subject is a non-human animal.
Parent Case Info
[0001] This application is a continuation-in-part of U.S. patent application Ser. No. 10/113,771 filed Apr. 1, 2002, which is a continuation of U.S. patent application Ser. No. 09/495,186 filed Feb. 1, 2000, issued as U.S. Pat. No. which is a continuation-in-part of U.S. Pat. application Ser. No. 09/432,948 filed Nov. 3, 1999, issued Aug. 8, 2000 as U.S. Pat. No. 6,100,244, which is a continuation of U.S. Pat. application Ser. No. 09/037,895 filed Mar. 10, 1998, issued Aug. 1, 2000 as U.S. Pat. No. 6,096,721 which is a continuation-in-part of U.S. patent application Ser. No. 08/755,092 filed Nov. 22, 1996, issued Mar. 10, 1998 as U.S. Pat. No. 5,726,160 which is a continuation of U.S. patent application Ser. No. 08/421,232 filed Apr. 13, 1995, now abandoned.
Continuations (3)
|
Number |
Date |
Country |
Parent |
09495186 |
Feb 2000 |
US |
Child |
10113771 |
Apr 2002 |
US |
Parent |
09037895 |
Mar 1998 |
US |
Child |
09432948 |
Nov 1999 |
US |
Parent |
08421232 |
Apr 1995 |
US |
Child |
08755092 |
Nov 1996 |
US |
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
10113771 |
Apr 2002 |
US |
Child |
10177398 |
Jun 2002 |
US |
Parent |
09432948 |
Nov 1999 |
US |
Child |
09495186 |
Feb 2000 |
US |
Parent |
08755092 |
Nov 1996 |
US |
Child |
09037895 |
Mar 1998 |
US |